Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.93 |
| ▸ | MAPT | P10636 | 9/20 | 0.93 |
| ▸ | MEN1 | O00255 | 7/20 | 0.93 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.93 |
| ▸ | GAA | P10253 | 6/20 | 0.93 |
| ▸ | THRB | P10828 | 4/20 | 0.93 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.93 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.93 |
| ▸ | POLB | P06746 | 2/20 | 0.65 |
| ▸ | GFER | P55789 | 2/20 | 0.63 |
| ▸ | RAD52 | P43351 | 2/20 | 0.63 |
| ▸ | ALDH1A3 | P47895 | 2/20 | 0.57 |
| ▸ | HTT | P42858 | 6/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.53 |
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.53 |
| ▸ | YWHAG | P61981 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
| ▸ | S100B | P04271 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6156455 | 0.98 | ALDH1A1 (0.96) | ALDH1A1MAPTMEN1KMT2AGAA | |
| SCHEMBL7031588 | 0.94 | ALDH1A1 (0.89) | ALDH1A1MAPTMEN1KMT2AGAA | |
| SCHEMBL6272228 | 0.92 | ALDH1A1 (0.86) | ALDH1A1MAPTMEN1KMT2AGAA | |
| Hydrochloric Acid SCHEMBL7051020 | 0.91 | ALDH1A1 (0.89) | ALDH1A1MAPTMEN1KMT2AGAA | |
| SCHEMBL15358737 | 0.90 | MAPT (0.81) | ALDH1A1MAPTMEN1KMT2AGAA | |
| Sulfuric Acid SCHEMBL6653587 | 0.88 | MAPT (0.78) | ALDH1A1MAPTMEN1KMT2AGAA | |
| SCHEMBL5357582 | 0.84 | MAPT (0.73) | ALDH1A1MAPTMEN1KMT2AGAA | |
| SCHEMBL12006386 | 0.83 | MAPT (0.71) | ALDH1A1MAPTMEN1KMT2AGAA | |
| SCHEMBL25091069 | 0.83 | MAPT (0.71) | ALDH1A1MAPTMEN1KMT2AGAA | |
| SCHEMBL187881 | 0.83 | ALDH1A1 (0.71) | ALDH1A1MAPTMEN1KMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230285378-A1 | Anti-Viral Compounds | ABBVIE INC. (US) | 2023-09-14 | — | — | US | disclosed |
| EP-3814334-A1 | 4-SUBSTITUTED PHENYL-1,3,5-TRIAZINE DERIVATIVES AS MODULATORS OF TRK RECEPTORS | Alzecure Pharma AB (SE) | 2021-05-05 | — | — | EP | disclosed |
| EP-3438106-A1 | ANTI-VIRAL COMPOUNDS | AbbVie Ireland Unlimited Company (IE) | 2019-02-06 | — | — | EP | disclosed |
| US-20190015402-A1 | Anti-Viral Compounds | ABBVIE INC. (US) | 2019-01-17 | — | — | US | disclosed |
| US-10039754-B2 | Anti-viral compounds | ABBVIE INC. (US) | 2018-08-07 | — | — | US | disclosed |
| US-10028937-B2 | Anti-viral compounds | ABBVIE INC. (US) | 2018-07-24 | — | — | US | disclosed |
| US-20170273922-A1 | UREA AND BIS-UREA BASED COMPOUNDS AND ANALOGUES THEREOF USEFUL IN THE TREATMENT OF ANDROGEN RECEPTOR MEDIATED DISEASES OR DISORDERS | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2017-09-28 | — | — | US | disclosed |
| US-20170157105-A1 | Anti-Viral Compounds | ABBVIE INC. (US) | 2017-06-08 | — | — | US | disclosed |
| US-20170157104-A1 | Anti-Viral Compounds | ABBVIE INC. (US) | 2017-06-08 | — | — | US | disclosed |
| EP-2678334-B1 | ANTI-VIRAL COMPOUNDS | ABBVIE BAHAMAS LTD (BS) | 2017-03-22 | — | — | EP | disclosed |
| CN-101768130-A | Derivatives containing aminomethyl-5-membered aromatic heterocycle-4-carboxylic acid, preparation method, drug combination and application thereof | TIANJIN INST PHARM RESEARCH | 2010-07-07 | — | — | CN | disclosed |
| US-7671058-B2 | N-(3,4-disubstituted phenyl) salicylamide derivatives | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2010-03-02 | — | — | US | disclosed |
| US-7671058-B2 | N-(3,4-disubstituted phenyl) salicylamide derivatives | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2010-03-02 | — | — | US | disclosed |
| US-7442698-B2 | Substituted heterocyclic compounds and methods of use | AMGEN INC. (US) | 2008-10-28 | — | — | US | disclosed |
| US-7442698-B2 | Substituted heterocyclic compounds and methods of use | AMGEN INC. (US) | 2008-10-28 | — | — | US | disclosed |
| US-20080227784-A1 | N-(3,4-disubstituted phenyl) salicylamide derivatives | INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) | 2008-09-18 | — | — | US | disclosed |
| US-20080227784-A1 | N-(3,4-disubstituted phenyl) salicylamide derivatives | INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) | 2008-09-18 | — | — | US | disclosed |
| US-20050171102-A1 | Semicarbazide derivatives for combating thromboembolic diseases | MERCK PATENT GMBH (DE) | 2005-08-04 | — | — | US | disclosed |
| EP-1501814-A1 | SEMICARBAZIDE DERIVATIVES FOR COMBATING THROMBOEMBOLIC DISEASES | MERCK PATENT GmbH (DE) | 2005-02-02 | — | — | EP | disclosed |
| WO-2003093254-A1 | SEMICARBAZIDE DERIVATIVES FOR COMBATING THROMBOEMBOLIC DISEASES | MERCK PATENT GMBH (DE) | 2003-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171102-A1 | Semicarbazide derivatives for combating thromboembolic diseases | SERPINC1, F11, F12 | ALDH1A1 212/4885MAPT 4863/4885MEN1 201/4885 |
| US-10028937-B2 | Anti-viral compounds | HAVCR2, EIF2AK2, MAVS | ALDH1A1 2858/4885MAPT 2833/4885MEN1 4681/4885 |
| US-20230285378-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | ALDH1A1 2858/4885MAPT 2833/4885MEN1 4681/4885 |
| US-20170157105-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | ALDH1A1 2858/4885MAPT 2833/4885MEN1 4681/4885 |
| US-20170157104-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | ALDH1A1 2858/4885MAPT 2833/4885MEN1 4681/4885 |
| US-20170273922-A1 | UREA AND BIS-UREA BASED COMPOUNDS AND ANALOGUES THEREOF USEFUL IN THE TREATMENT OF ANDROGEN RECEPTOR MEDIATED DISEASES OR DISORDERS | AR, UTS2R, SHBG | ALDH1A1 1583/4885MAPT 367/4885MEN1 1148/4885 |
| US-20080227784-A1 | N-(3,4-disubstituted phenyl) salicylamide derivatives | STAT6, RELA, NFKB2 | ALDH1A1 2263/4885MAPT 4713/4885MEN1 4100/4885 |
| US-20190015402-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | ALDH1A1 2858/4885MAPT 2833/4885MEN1 4681/4885 |
| US-10039754-B2 | Anti-viral compounds | HAVCR2, EIF2AK2, MAVS | ALDH1A1 2858/4885MAPT 2833/4885MEN1 4681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.